Lipid nanoparticle-encapsulated Dnai1 mRNA rescues ciliary activity in primary ciliary dyskinesia mouse cell models
Journal of Cell Science · 2025
DOI: 10.1242/jcs.264068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Science, 2025. Verfasst von Amanda J Smith und 10 weiteren Autor:innen. Beteiligte Einrichtung: Marsico Lung Institute/Cystic Fibrosis Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Hauptthemen laut MEDLINE: RNA, Messenger, Cilia, Nanoparticles, Ciliary Motility Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ReCode Therapeutics, University of North Carolina at Chapel Hill.
Abstract (Originalsprache)
Primary ciliary dyskinesia (PCD) is a rare, genetically heterogenous disorder resulting from dysfunctional motile cilia that is characterized by chronic, progressive lung disease with currently no corrective therapies available. Here, we test the efficacy of selective organ targeting lipid nanoparticles (SORT-LNPs) that were optimized for potency and delivery to respiratory cells containing an mRNA encoding an axonemal protein to rescue ciliary activity in a murine culture model of PCD. Utilizing murine nasopharyngeal epithelial cell (mNPEC) cultures isolated from a conditional Dnai1 knockout mouse model of the known human PCD-associated gene DNAI1 homolog, we tested if SORT-LNPs containing an optimized Dnai1 mRNA could rescue ciliary activity. Treatment of differentiating and well-differentiated Dnai1 knockout mNPECs with SORT-LNP-Dnai1 mRNA led to a dose-dependent increase in levels of DNAI1 protein and incorporation into ciliary axonemes, resulting in rescued ciliary activity with normal ciliary beat frequency that persisted for over 3 weeks. These data support further clinical development of an mRNA-based therapeutic with LNP-mediated delivery as a treatment for individuals with PCD with disease-causing DNAI1 mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Marsico Lung Institute/Cystic Fibrosis Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Presently ReCode Therapeutics, Durham, NC 27701.
- ReCode Therapeutics, Menlo Park, CA 94025, USA.
- Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
- Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
ORCID-Profile: Amanda J Smith, Mirko Hennig, Daniella Ishimaru, Lawrence E Ostrowski
Förderung
- ReCode Therapeutics
- University of North Carolina at Chapel Hill
Zitieren
APA
Smith, A. J., Sears, P. R., Hennig, M., Bhattacharjee, R. B., Yin, W., Golliher, H., Ishimaru, D., Lombana, T. N., Lockhart, D. J., Wustman, B. A., & Ostrowski, L. E. (2025). Lipid nanoparticle-encapsulated Dnai1 mRNA rescues ciliary activity in primary ciliary dyskinesia mouse cell models. Journal of Cell Science. https://doi.org/10.1242/jcs.264068
Vancouver
Smith AJ, Sears PR, Hennig M, Bhattacharjee RB, Yin W, Golliher H, et al. Lipid nanoparticle-encapsulated Dnai1 mRNA rescues ciliary activity in primary ciliary dyskinesia mouse cell models. Journal of Cell Science. 2025. doi:10.1242/jcs.264068
BibTeX
@article{Smith2025,
author = {Smith, Amanda J and Sears, Patrick R and Hennig, Mirko and Bhattacharjee, Rumpa B and Yin, Weining and Golliher, Hannah and Ishimaru, Daniella and Lombana, T Noelle and Lockhart, David J and Wustman, Brandon A and Ostrowski, Lawrence E},
title = {Lipid nanoparticle-encapsulated Dnai1 mRNA rescues ciliary activity in primary ciliary dyskinesia mouse cell models},
journal = {Journal of Cell Science},
year = {2025},
doi = {10.1242/jcs.264068}
}
EUVIMED